The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Capricor Therapeutics, Inc. (CAPR) Shareholders

Core Viewpoint - The Gross Law Firm is notifying shareholders of Capricor Therapeutics, Inc. regarding a potential class action lawsuit due to misleading statements related to the company's lead cell therapy candidate, deramiocel, and its subsequent FDA response [1][3]. Group 1: Allegations and Impact - Shareholders who purchased shares of Capricor during the class period from October 9, 2024, to July 10, 2025, are encouraged to contact the firm for possible lead plaintiff appointment [1][3]. - The complaint alleges that Capricor provided investors with misleading information about deramiocel's potential to receive a Biologics License Application (BLA) from the FDA while concealing adverse facts regarding its Phase 2 HOPE-2 trial data [3]. - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness, Capricor's stock price fell from $11.40 to $7.64 per share [3]. Group 2: Next Steps for Shareholders - The deadline for shareholders to register for the class action is September 15, 2025, and they will be enrolled in a portfolio monitoring system for updates on the case [4]. - There is no cost or obligation for shareholders to participate in the case, and registration is encouraged to ensure they are informed throughout the legal process [4]. Group 3: Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].